- Home
- GDYN vs KURA Comparison
GDYN vs KURA Comparison
Compare GDYN & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDYN | KURA |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.5M | 1.1B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GDYN | KURA |
|---|---|---|
| Price | $7.74 | $11.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $10.67 | ★ $25.56 |
| AVG Volume (30 Days) | 852.8K | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $111,283,000.00 | $67,482,000.00 |
| Revenue This Year | $10.16 | $28.28 |
| Revenue Next Year | $10.84 | $106.37 |
| P/E Ratio | $385.00 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $5.11 | $7.36 |
| 52 Week High | $10.21 | $13.90 |
Technical Indicators
Market Signals| Indicator | GDYN | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 50.06 |
| Support Level | $7.61 | $11.03 |
| Resistance Level | $8.22 | $12.22 |
| Average True Range (ATR) | 0.27 | 0.49 |
| MACD | -0.08 | -0.15 |
| Stochastic Oscillator | 15.98 | 30.81 |
Price Performance
Historical ComparisonAbout GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.